

# Modulation of food intake by selective TAS2R stimulation in rat

CARME GRAU-BOVÉ<sup>1</sup>, ALBA MIGUÉN-GÓMEZ<sup>1</sup>, CARLOS ALBERTO GONZÁLEZ<sup>1</sup>, MARTA SIERRA-CRUZ<sup>1</sup>, ESTHER RODRÍGUEZ-GALLEGO<sup>1</sup>, RAUL BELTRÁN-DEBÓN<sup>1</sup>, MARIA TERESA BLAY<sup>1</sup>, XIMENA TERRA<sup>1</sup>, ANNA ARDEVOL<sup>1</sup>, MONTSERRAT PINENT<sup>1</sup>

<sup>1</sup>Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Tarragona, Spain

carme.grau@urv.cat

INTRODUCTION

Metabolic surgery modulates the enteroendocrine hormone profile, which leads, among other effects, to changes in food intake.

Bitter taste receptors (TAS2Rs) have been identified in extra-oral locations such as the gastrointestinal tract, while their specific stimulation has been linked to the control of ghrelin secretion.


We hypothesize that the optimal stimulation of bitter taste receptors could help to modulate enteroendocrine secretions, thus leading to the regulation of food intake.

AIM


We aimed to evaluate the response to defined agonists for the human bitter taste receptors hTAS2R5, hTAS2R14 and hTAS2R39 on:

- Enteroendocrine secretions from rat intestinal segments
- In vivo food intake experiments with rats.

## 1A: Ex vivo enteroendocrine secretions



## 1B: In vivo food intake studies




**Figure 1. Graphical representation of the experimental design.** (A). For ex vivo enteroendocrine secretion studies we used duodenum and ileum segments from rats and we treated them with different bitter agonists. (B) For in vivo food intake studies, we treated the rats by oral gavage with different bitter agonists and we measured their food intake at three time points: 3h, 20h and 24h.

**Table 1. List of bitter agonists used and their defined receptor.**


Agonists used	Bitter receptor	Agonists used	Bitter receptor
1,10-Phenanthroline	hTAS2R5	EGCG	hTAS2R5 and hTAS2R39
Thiamine	hTAS2R39	Flufenamic acid	hTAS2R14
ECg	hTAS2R39	Protocatechuic acid	hTAS2R14
Epicatechin	hTAS2R5 and hTAS2R39	Vanillic acid	hTAS2R14
B2 gallate	hTAS2R5 and hTAS2R39	Procyanidin B2	Undefined

METHODS


## 2A. hTAS2R5 agonist




## 2B. hTAS2R39 agonist




## 2C. hTAS2R5 and hTAS2R39 agonists




## 2E. hTAS2R14 agonists



## 2D. CCK secretion




## 2F. Undefined agonist




**Figure 2. Enteroendocrine secretions.** (A) Enteroendocrine hormones released in response to 1,10-Phenanthroline 150  $\mu$ M. (B) Enteroendocrine hormones released in response to Thiamine 1mM. (C) GLP1 released in response to Epicatechin 1mM, B2gallate 20 mM, 1,10-Phenanthroline 150 mM + Thiamine 1 mM. (D) CCK released in response to Epicatechin 1mM, B2gallate 20 mM. (E) GLP1 released in response to Flufenamic acid 50  $\mu$ M, protocatechuic acid 300  $\mu$ M, Vanillic acid 300  $\mu$ M. (F) GLP1 (red columns) and CCK (blue columns) released in response to B2 67 or 300  $\mu$ M, or B2 300  $\mu$ M + epicatechin 1 mM.


## 3A. hTAS2R5 agonist




## 3B. hTAS2R14 and hTAS2R39 agonists




## 3C. hTAS2R39 > hTAS2R5 agonists




## 3E. hTAS2R5 > hTAS2R39 agonists



## 3D. FI reduction (%)



## 3F. FI increase (%)



**Figure 3. Food intake modulation.** In all graphics, white columns are food intake in response to vehicle (tap water). Darker columns are food intake in response to acute doses of: (A) 1,10-Phenanthroline 200 mg/kg. (B) Vanillic acid 252 mg/kg (grey columns) and Vanillic acid + Epicatechin (252+244 mg/kg) (black columns). (C) Epicatechin+B2+ECg (200+62+18 mg/kg). (D) Epicatechin 244 mg/kg (grey) and 300 mg/kg (black). (E) Epicatechin + ECg (234+14 mg/kg). (F) Epicatechin+B2 (213+62 mg/kg).

RESULTS

CONCLUSION

We conclude that bitter taste receptors can be stimulated with various agonists to activate differential enteroendocrine secretions that modulate food intake.

This work has been supported by AGL2017-83477-R from the Spanish Ministerio de Ciencia Innovación y Universidades and R2B2018/03co-funded by the FEDER programme of the Generalitat de Catalunya and the URV.

